145 related articles for article (PubMed ID: 34290709)
1. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
Thakur A; Scholler J; Kubicka E; Bliemeister ET; Schalk DL; June CH; Lum LG
Front Immunol; 2021; 12():690437. PubMed ID: 34290709
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
[TBL] [Abstract][Full Text] [Related]
3. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
4. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
[TBL] [Abstract][Full Text] [Related]
6. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
7. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
[TBL] [Abstract][Full Text] [Related]
8. Depletion of T cells
Klopp A; Schreiber S; Kosinska AD; Pulé M; Protzer U; Wisskirchen K
Front Immunol; 2021; 12():734246. PubMed ID: 34691041
[TBL] [Abstract][Full Text] [Related]
9. An engineering strategy to target activated EGFR with CAR T cells.
Dobersberger M; Sumesgutner D; Zajc CU; Salzer B; Laurent E; Emminger D; Sylvander E; Lehner E; Teufl M; Seigner J; Bobbili MR; Kunert R; Lehner M; Traxlmayr MW
Cell Rep Methods; 2024 Apr; 4(4):100728. PubMed ID: 38492569
[TBL] [Abstract][Full Text] [Related]
10. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Nellan A; Rota C; Majzner R; Lester-McCully CM; Griesinger AM; Mulcahy Levy JM; Foreman NK; Warren KE; Lee DW
J Immunother Cancer; 2018 Apr; 6(1):30. PubMed ID: 29712574
[TBL] [Abstract][Full Text] [Related]
11. [In vitro and in vivo validation of cytotoxicity of targeting human epidermal growth factor receptor-2 chimeric antigen receptor T (HER2-CAR-T) cells].
Zhang Y; Xi W; Wang P; Zhao X; Zheng R; Liang S; Meng R; Yan B; Yang A
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):289-295. PubMed ID: 38710512
[TBL] [Abstract][Full Text] [Related]
12. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.
Thakur A; Norkina O; Lum LG
Cancer Immunol Immunother; 2011 Dec; 60(12):1707-20. PubMed ID: 21713642
[TBL] [Abstract][Full Text] [Related]
13. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
Biomed Pharmacother; 2024 Jun; 175():116718. PubMed ID: 38744221
[TBL] [Abstract][Full Text] [Related]
14. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
Hegde M; Joseph SK; Pashankar F; DeRenzo C; Sanber K; Navai S; Byrd TT; Hicks J; Xu ML; Gerken C; Kalra M; Robertson C; Zhang H; Shree A; Mehta B; Dakhova O; Salsman VS; Grilley B; Gee A; Dotti G; Heslop HE; Brenner MK; Wels WS; Gottschalk S; Ahmed N
Nat Commun; 2020 Jul; 11(1):3549. PubMed ID: 32669548
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cells and BiTEs in solid tumors: challenges and perspectives.
Edeline J; Houot R; Marabelle A; Alcantara M
J Hematol Oncol; 2021 Apr; 14(1):65. PubMed ID: 33874996
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.
Vaishampayan U; Thakur A; Rathore R; Kouttab N; Lum LG
Prostate Cancer; 2015; 2015():285193. PubMed ID: 25802762
[TBL] [Abstract][Full Text] [Related]
17. Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor.
Wang X; Liu G; Shi X; Wang Y; Jiang B; Liu W; Dai A; Zhang X; Yu F
Hum Cell; 2024 May; ():. PubMed ID: 38691335
[TBL] [Abstract][Full Text] [Related]
18. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
19. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function.
Johnson LR; Lee DY; Eacret JS; Ye D; June CH; Minn AJ
Cell; 2021 Sep; 184(19):4981-4995.e14. PubMed ID: 34464586
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.
Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS
Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
